DiscoveryProbe™ FDA-approved Drug Library: High-Content Screening and Drug Repositioning Benchmarks

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) contains 2,320 bioactive compounds, each clinically approved by regulatory agencies such as the FDA, EMA, HMA, CFDA, and PMDA, or listed in pharmacopeias (ApexBio). The library is supplied as pre-dissolved 10 mM DMSO solutions for streamlined high-throughput and high-content screening applications. Benchmark studies demonstrate its utility in drug repositioning and target identification, exemplified by the disruption of 14-3-3 protein–BAD interactions in colorectal cancer (He et al., 2023). Stability data confirm 12 months of integrity at -20°C and up to 24 months at -80°C. Mechanistic diversity—including enzyme inhibitors, receptor modulators, and signal pathway regulators—enables broad applications across cancer, neurodegeneration, and rare diseases (contrast).

Biological Rationale

Drug discovery increasingly leverages libraries composed of FDA-approved compounds to accelerate the path from bench to clinic. Clinically validated molecules have established pharmacokinetics, safety, and mechanism-of-action data. Repositioning existing drugs reduces the attrition rate seen in de novo chemical entity development (He et al., 2023). The DiscoveryProbe™ FDA-approved Drug Library is designed to support high-throughput screening (HTS) and high-content screening (HCS), which are essential for identifying compounds that modulate disease-relevant pathways. This approach is especially valuable in oncology and neurodegenerative disorders, where rapid evaluation of chemotherapeutic or neuroprotective potential is needed. By integrating compounds with well-characterized targets, including receptor agonists/antagonists and enzyme inhibitors, the library supports both phenotypic and target-based screening campaigns.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

This compound library encompasses a broad spectrum of established pharmacological mechanisms. Representative mechanisms include:

• Receptor agonists and antagonists (e.g., beta-blockers, opioid antagonists): These modulate signal transduction in target tissues.
• Enzyme inhibitors (e.g., statins, kinase inhibitors): These block enzymatic activities critical for disease progression.
• Ion channel modulators (e.g., calcium channel blockers): These alter cellular excitability or signaling.
• Signal pathway regulators (e.g., mTOR inhibitors): These affect networks controlling cell survival, proliferation, and apoptosis.

An exemplary application is the identification of compounds disrupting 14-3-3 protein–BAD interactions, which regulate apoptosis in cancer cells (He et al., 2023). The library contains drugs such as doxorubicin, metformin, and atorvastatin, each with well-documented bioactivity and safety profiles.

Evidence & Benchmarks

• An HTS campaign using an FDA-approved drug library (1971 compounds) identified terfenadine, penfluridol, and lomitapide as disruptors of 14-3-3:BAD complexes in colorectal cancer cell lines (He et al., 2023, DOI).
• The screening assay achieved a Z’-score of 0.52, indicating robust assay performance (He et al., 2023, Table 1).
• Compounds are provided as 10 mM solutions in DMSO, stable at -20°C for 12 months and at -80°C for up to 24 months (ApexBio).
• Cited applications include drug repositioning for cancer and neurodegenerative disease models, as well as identification of covalent and non-covalent inhibitors (contrast).
• All compounds are approved or recognized by regulatory authorities (FDA, EMA, HMA, CFDA, PMDA) or listed in pharmacopeias (ApexBio).

This article extends the mechanistic context provided by DiscoveryProbe™: Unraveling Compound Mechanisms by focusing on HTS/HCS parameters and stable storage conditions validated in recent preclinical screens.

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library supports a spectrum of research needs:

• Drug repositioning screening: Rapid identification of new indications for approved drugs.
• Pharmacological target identification: Profiling compound–target interactions using HTS/HCS.
• Cancer research drug screening: Discovery of pro-apoptotic and chemosensitizing agents.
• Neurodegenerative disease drug discovery: Identification of neuroprotective or disease-modifying compounds.
• Signal pathway regulation and enzyme inhibitor screening: Mechanistic studies in disease models.

Common Pitfalls or Misconceptions

• This library does not include unapproved or investigational new chemical entities.
• Pre-dissolved solutions are in DMSO; compounds insoluble in aqueous buffers may require additional formulation.
• Compounds are intended for in vitro research use and are not certified for in vivo or clinical applications without additional validation.
• HTS/HCS results require orthogonal validation; false positives can occur due to off-target effects.
• Library does not cover all possible mechanisms or rare orphan drugs outside major pharmacopeias/regulatory lists.

Workflow Integration & Parameters

The DiscoveryProbe™ library is engineered for compatibility with diverse experimental workflows:

• Formats available: 96-well microplates, deep well plates, and 2D barcoded screw-top storage tubes.
• Concentration: All compounds provided as 10 mM DMSO stock solutions.
• Shipping: On blue ice for evaluation samples; standard shipping at room temperature or on blue ice upon request.
• Storage: -20°C (12 months) or -80°C (24 months) for optimal compound stability.
• Assay integration: Compatible with standard HTS/HCS automation platforms and liquid-handling systems.
• Data management: 2D barcode tracking for sample traceability and informatics integration.

For deeper insight into translational screening applications and strategic integration, see Unlocking Translational Breakthroughs: Mechanistic Insights, which this article updates with recent evidence on colorectal cancer drug repositioning screens.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a validated, stable, and mechanistically diverse resource for high-throughput and high-content drug screening. Its inclusion of only clinically approved or pharmacopeia-listed compounds provides a lower-risk foundation for drug repositioning and target identification across oncology, neurodegeneration, and beyond. Ongoing benchmark studies, such as disruption of 14-3-3 protein–BAD interactions in colorectal cancer, highlight its translational value (He et al., 2023). As the demand for rapid, mechanistically informed screening grows, this resource will remain central to translational pharmacology workflows. For product details and ordering, visit the DiscoveryProbe™ FDA-approved Drug Library product page.